anti-PD-L1 antibody and anti-PD-1 antibody (Quartett)
Quartett’s website is here
anti-PD-L1 Rabbit Monoclonals -Successfully tested in national and international studies and ring trials
Over the last years the research of Programmed Death Ligand 1 (PD-L1, also known as CD274 or B7-H1) became more attractive because of a potential role in cancer therapy. The 40 kDa transmembrane protein binds to the receptor Programmed death-1 (PD-1), which is a T cell immune checkpoint. The activation of the pathway leads to an inhibition of the T cell activation to avoid an autoimmune response. Several tumor cell and tumor-infiltrating immune cells exploit this mechanism to evade destruction and to be resistant to CD8+ T cellmediated lysis.
Human tonsil stained with anti-PD-L1 (QR1)
quartett offers with PD-L1 (clone QR1) a new monoclonal rabbit antibody that is reactive in formalin-fixed paraffin-embedded human tissues. The antibody is a predictive marker of different cancer types, including sentinel lymph node melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and triple negative breast cancer cells (TNBC) where it provides a membranous and cytoplasmic staining.
anti-PD-1 Rabbit Monoclonals -New marker for human PD-1
Programmed Death 1 (PD-1, CD279) is a transmembrane protein functioning as surface receptor for its ligands PD-L1 and PD-L2. PD-1 is expressed mainly on activated T-cells, B-cells and myeloid cells. PD-1 is an immune checkpoint and plays a crucial role in down regulation of the immune system through inhibition of T-cell activation, which in turn reduces autoimmunity. Some tumor cells use this mechanism to prevent apoptosis by inhibiting T-cells directed to them.
PD-1 (QR2) is a useful marker for angioimmunoblastic lymphoma. Furthermore, increased expression of PD-1 has been found to be associated with poor prognosis in hepatocellular carcinoma and renal cell carcinoma.
Treatments targeting PD-1 have shown encouraging results in breast cancer, non-small cell lung cancer (NSCLC) and melanoma.
Human lymph node stained with anti-PD-1 (QR2)
|1-PR294-02||PD-1 (QR2)||concentrate||100 μl||In Preparation|
|1-PR294-05||PD-1 (QR2)||concentrate||500 μl|
|1-PR294-07||PD-1 (QR2)||concentrate||1 ml|
|2-PR294-07||PD-1 (QR2)||ready-to-use||1 ml|
|2-PR294-10||PD-1 (QR2)||ready-to-use||3 ml|
|2-PR294-13||PD-1 (QR2)||ready-to-use||7 ml|
Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.